The anthracycline drugs -- long a mainstay of breast cancer chemotherapy -- only benefit a minority of women and should be mostly scrapped, a researcher said here.Read the full article here:
The continued use of the drugs "on a one-size-fits-all approach is just crazy and it's medically dangerous," said Dennis Slamon, M.D., Ph.D., of the University of California at Los Angeles.
No comments:
Post a Comment